How this UVIC research centre is driving progress in biomedical science


The University of Victoria Genome B.C. Proteomics Centre has been providing mass spectrometry services that have allowed revolutionary biomedical and life science research to happen for over three decades, but there are still some missing links.

As the hub of the Pan-Canadian Proteomics Centre, the University of Victoria has conducted research that has been used to further the treatment of many conditions and diseases, including cardiovascular disease, cancer and infections.

It has also been a pillar of B.C.’s $1.6B life sciences sector, helping B.C. to be a global leader within the biomedical and life science industries.

With PacifiCan’s support, the University of Victoria Genome B.C. Proteomics Centre is taking it to the next level by implementing innovative, state of the art new technology.

The Bruker timsTOF fleX MALDI-2 mass spectrometer, the first installed in Canada, will provide molecular spatial imaging for advancements in cancer research, drug development, personalized medicine, and so much more.

$1.2 million in PacifiCan funding helped the University of Victoria Genome B.C. Proteomics Centre remain at the forefront of life sciences and biomedical research through:

 

 

Headshot imaeg of Dr. David Goodlett, Professor, University of Victoria and Director, University of Victoria - GBC Proteomics Centre. His quote reads Funding from PacifiCan supported our investment in a cutting-edge Mass Spectrometry Imaging (MSI) instrument that provides the spatial distribution of molecules in tissues. This technology offers novel solutions to oncology researchers across Canada, as well as supporting the development of new therapies and tools from companies in B.C. and Canada.

 


On social media

Page details

Date modified: